http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2657636-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_927cef905d17253d40a2e1a4dbfc8296 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_764c37797762f79bedf08832dbf3a65a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C327-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-63 |
| filingDate | 2006-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2bbea8535f5f72aef6b493a3328b16b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fac05669316effe24d3e388dfb9f027a |
| publicationDate | 2008-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2657636-A1 |
| titleOfInvention | Positively charged water soluble prodrugs of ibuprofen with very fast skin penetration rate |
| abstract | The novel positively charged pro-drugs of ibuprofen in the general formul a (I) "Structure 1" were designed and synthesized. The compounds of the gene ral formula (I) "Structure 1" indicated above can be prepared from functiona l derivatives of ibuprofen, (for example acid halides or mixed anhydrides), by reaction with suitable alcohols, thiols, or amines. The positively charge d amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head gr oup of membranes and pushes the pro-drug into the cytosol. The experiment re sults suggest that the pro-drug, diethylaminoethyl 2-(p-isobutylphenyl) prop ionate.AcOH, diffuses through human skin -250 times faster than ibuprofen it self and -125 times faster than ethyl 2-(p-isobutylphenyl) propionate. In pl asma, more than 90% of these pro-drugs can change back to the drug in a few minutes. The prodrugs can be used medicinally in treating any ibuprofen-trea table conditions in humans or animals and be administered not only orally, b ut also transdermally for any kind of medical treatments and avoid most of t he side effects of ibuprofen, most notably GI disturbances such as dyspepsia , gastroduodenal bleeding, gastric ulcerations, and gastritis. Controlled tr ansdermal administration systems of the prodrugenables the ibuprofen to reac h constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of ibuprofen. |
| priorityDate | 2006-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 75.